Skip to content

Vericel VCEL Common stock, shares authorized (in shares)

Common stock, shares authorized (in shares) at other companies

Enovis logo
EnovisENOV
Globus Medical logo
Globus MedicalGMED

Other financials

Income statement

See full
Revenue$68.4M+30.1%
Gross profit$49.3M+35.8%
Operating income-$8.1M+37.0%
Net income-$6.3M+44.0%
EPS (diluted)-$0.12+47.8%

Balance sheet

See full
Cash & equivalents$109.3M+37.1%
Total debt$95.0M-4.6%
Total equity$356.2M+20.6%
Total assets$485.6M+14.4%

Cash flow

See full
Operating cash flow$16.4M+148%
CapEx$1.3M-91.2%
Free cash flow$15.1M+299%

Valuation

See full
Market cap$2.13B-26.8%

Profitability

See full
Gross margin74.8%+2.3pp
Operating margin5.4%+4.6pp
Net margin7.3%+6.1pp
FCF margin16.3%

Returns & leverage

See full
Return on equity6.6%+5.5pp
Debt / equity0.3×-0.1×
Current ratio5.2×+0.2×

Where this comes from

Reported directly by Vericel in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.

The official record: Vericel’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vericel's common stock, shares authorized (in shares).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vericel's common stock, shares authorized (in shares)?
Vericel (VCEL) reported common stock, shares authorized (in shares) of $75M in Q1 2026.
How has Vericel's common stock, shares authorized (in shares) changed year-over-year?
Vericel's common stock, shares authorized (in shares) decreased by 0.0% year-over-year, from $75M to $75M.
What is the long-term trend for Vericel's common stock, shares authorized (in shares)?
Over 5 years (2020 to 2025), Vericel's common stock, shares authorized (in shares) has grown at a 0.0% compound annual growth rate (CAGR), from $75M to $75M.